Jan 25, 2022 / 01:00PM GMT
Hans Peter Bohn - PCI Biotech Holding ASA - Independent Chairman
Good afternoon, and welcome to this webcast from PCI Biotech. To those who don't know me, my name is Hans Peter Bohn, I'm the Chairman of the Board. And with me today, I have our CEO, Per Walday; our CFO, Ronny Skuggedal; and last but not least, our Chief Medical Officer, Dr. Amir Snapir.
We will be hosting this webcast to elaborate on our decisions to stop the RELEASE trial with our lead product, fimaCHEM in resectable -- unresectable biliary duct cancer. This decision was taken last night at an extraordinary Board meeting, and it came as a result of new details from the TOPAZ-1 study that we disclosed at the ASCO meeting in San Francisco at midnight before Saturday, just before the weekend.
It goes without saying that the decision to stop RELEASE will imply that fimaVACC and fimaNAc will step up to the forefront of the PCI Biotech's activity going forward. But today, we are not prepared to reveal any new information about this. We will revert or refer to the 3 quarter report, where we disclosed that the clinical proof-of
PCI Biotech Holding ASA Update on RELEASE Trial Call Transcript
Jan 25, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers